Furthermore, we observed a significantly abbreviated APD90 in ISO-stimulated cardiomyocytes from SCN10A−/− compared with WT (P<0.05). Preincubation with the both inhibitors significantly reversed the ISO-dependent enhancement of INaL, APD90 and CaSpF in WT myocytes, but not in SCN10A−/−. In conclusion, we show for the first time upregulation of NaV1.8, its colocolization and interaction with CaMKII in human HF. The NaV1.8 influences cellular electrophysiology by prolonging APD, increasing ryanodine receptor leakiness and thereby cellular proarrhythmogenic events in HF cardiomyocytes. Specific and pharmacological inhibition of NaV1.8 using novel inhibitors exerts potent antiarrhythmic effects. Thus, inhibition of NaV1.8 may be a novel specific antiarrhythmic approach under conditions of HF that merits further investigation. Background: Vitamin B12 deficiency in patients with heart failure (HF) might be underestimated. These patients may have "falsely" normal vitamin B12 serum levels due to coexisting oxidative stress and hepatic dysfunction. Methylmalonic acid (MMA) has been identified in several studies as an early indicator of vitamin B12 deficiency. Furthermore, it seems to be a biomarker of oxidative stress and mitochondrial dysfunction. Data regarding vitamin B12 and MMA in patients with HF are scarce. Aim: To investigate vitamin B12 and MMA serum levels in HF patients. Methods: 47 consecutive patients admitted to our hospital with symptoms and signs of acute decompensated heart failure were included in the study. Demographic and clinical characteristics as well as echocardiographic parameters were recorded. Blood samples were collected during the first 24 hours of hospitalization and complete blood count, creatinine, vitamin B12, NT-pro BNP and MMA levels were measured. A total of 12 healthy individuals (blood donors) constituted the control group, whereby MMA serum levels were also measured. Results: Preliminary analysis of data among 47 HF patients (aged 70.5±12.5 years; 50% with ischemic cardiomyopathy) indicated typical systolic dysfunction (reduced left ventricular ejection fraction-LVEF <40%, HFrEF) in the majority (77.7%) of patients, mild systolic dysfunction (mid-range LVEF 40-49%, HFmrEF) in 8.3% and preserved systolic function (preserved LVEF ≥50%, HFpEF) in 11.1%; right heart failure was present in 57.4%. Mean hematocrit was 38.2±7.9%, creatinine 1.17±0.31 mg/dl, and NT-proBNP levels 4694.4±4260.1 pg/ml. Vitamin B12 levels averaged 358.8±221.8 pg/ml. MMA levels were 37.1±10.1 ng/ml in HF patients and 28.6±2.7 ng/ml in the control group (p=0.0042). In patients with vitamin B12 at lower normal levels (<350 pg/ml), MMA was high (mean 39.4±9.4 ng/ml) and in patients with higher normal vitamin B12 levels (>351 pg/ml), MMA levels were low (mean 33.6±9.3 ng/ml, p=0.08), but still higher than control patients ( Figure) . Background: Poland belongs to the countries with the diagnosis of familial hypercholesterolemia (FH) patients less than 2%, and the real FH prevalence in still unknown. On the basis of limited data from available studies, in accordance with the criteria issued by the Dutch Lipids Clinics Network (DLCN), FH has been diagnosed in approximately 1:250 individuals aged 20-79 years, which corresponds roughly to a total of about 125,000 FH patients in the Polish population. Purpose: We aimed to verify the prevalence of FH in adult Polish patients based on the data from the largest Polish population-based surveys -LIPIDO-GRAM2004 &2006 studies. Methods: The LIPIDOGRAM2004 and LIPIDOGRAM2006 studies were population-based surveys, which assessed the prevalence of dyslipidaemia among adult patients under the care of family physicians across 444 practices in Poland. 34217 patients (17065 in 2004 and 17152 in 2006) older than 18 years, recruited by 675 study physicians, were analyzed to estimate the prevalence of FH with available DLCN criteria, including low-density lipoprotein cholesterol (LDL-C) and personal history of premature atherosclerotic cardiovascular disease. For individuals reporting statin use, we multiplied their LDL-C level by 1.43 to estimate untreated LDL-C levels, as was previously done by Benn, and Edwards and Moore. Results were extrapolated to the 31,532,051 Polish adults ≥18 years of age (based on Central Statistical Office data on the population of Poland, June 30th 2016). Results: 33689 patients were included to the final analysis (some data were excluded due to duplication as well as due to triglycerides levels >400 mg/dl in LIPI-DOGRAM2004 study, where LDL-C was measured with the Friedewald formula). We found 199 patients with LDL-C ≥330 mg/dl (≥8.5 mmol/l) (8 pts. in DLCN criteria) (including 31 patients with positive clinical personal history of premature coronary artery disease -10 pts. in total), and 228 subjects with LDL-C: 250-329 mg/dL (6.5-8.4 mmol/l) and positive clinical personal history of premature coronary artery disease (7 pts. in total in DLCN criteria). The estimated overall prevalence of probable/definite FH (≥7 pts. in DLCN criteria) was 1,27% or 1 in 79, suggesting 400,457 Polish adults with FH or at the high risk of FH diagnosis. Conclusions: FH, defined with Dutch Lipid Clinic criteria available in LIPIDO-GRAM2004 and 2006 studies, might affect even 1 in 79 adults in Poland. Further studies, especially based on the future data from the Polish FH Registry -which has just been created as a part of EAS FHSC initiative, are necessary to confirm this data.
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